SHIFT Newsroom · UK

MHRA approves weekly Onswik insulin for adult type 2 diabetes

Catch-up: UK authorisation announced on 13 October 2026.

By SHIFT Newsroom · Published 19 October 2026

How we prepare and check newsroom articles · Report a correction

The MHRA authorised Onswik (insulin efsitora alfa), a once-weekly insulin treatment for adults with type 2 diabetes, on 13 October. For some patients, weekly treatment could reduce the number of injections compared with daily insulin.

This is a diabetes insulin approval, not an approval for weight management. Regulatory authorisation should also be distinguished from commercial supply and NHS access arrangements.

SHIFT’s take

What we think this could mean for you, and what remains uncertain.

Readers should keep diabetes treatment developments separate from claims about obesity medicines. The authorisation announcement alone does not confirm local availability.

Known facts

The MHRA announcement was published on 13 October 2026.

Sources and evidence

MHRA — Source date: 13 October 2026

← Back to SHIFT Newsroom